NCT04320693
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Approved for marketing

Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT04320693